Retention and Re-Engagement in Treatment for Addiction Following Serious Injection Related Infections (RETAIN)
Launched by BOSTON MEDICAL CENTER · Jul 3, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The RETAIN trial is a study designed to help people with Opioid Use Disorder (OUD) who have been hospitalized for serious infections related to injecting drugs, like bloodstream infections or bone infections. The goal is to test a new support program called Recovery Management Checkups (RMC), which has been adapted to better meet the needs of these patients. Many individuals struggle to stay in treatment after leaving the hospital, even though medications for OUD can significantly lower the risk of death and the chances of being readmitted to the hospital. This pilot study aims to see if the new RMC program is practical and acceptable for patients, while also gathering initial insights on how effective it is.
To be eligible for this study, participants must be between 18 and 65 years old, currently hospitalized at Boston Medical Center for a serious injection-related infection, and able to give informed consent. Participants will receive support through the adapted RMC program, which may help them stay on track with their recovery after leaving the hospital. This study is an important first step toward refining this program for future larger trials, ultimately aiming to help more people successfully manage their addiction and improve their health outcomes.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Between 18 and 65 years of age
- • Able to provide Informed Consent
- • Admitted to Boston Medical Center on any inpatient unit for an active serious injection related infection (SIRI) such as endocarditis, osteomyelitis, bacteremia, septic arthritis, epidural abscess or other serious infection in which two weeks or more of antibiotics are recommended
- Exclusion Criteria:
- • Not able to give informed consent
- • Cognitive ability (defined through Research Assistant (RA) determination)
- • Inability to complete assessments in English or Spanish (defined through RA determination).
- • Exclusion for any reason under PI discretion
- • Unable to provide names and contact information for at least two verifiable locator persons who will know where to find them in the future.
- • In police custody or expecting incarceration
About Boston Medical Center
Boston Medical Center (BMC) is a leading academic medical center located in Boston, Massachusetts, dedicated to providing high-quality, compassionate care to diverse populations. As a prominent clinical trial sponsor, BMC conducts innovative research aimed at advancing medical knowledge and improving patient outcomes across a wide range of specialties. With a commitment to health equity and access to care, BMC collaborates with various stakeholders, including academic institutions and industry partners, to facilitate groundbreaking studies and translate findings into effective treatments. Its robust infrastructure and experienced research teams ensure adherence to the highest ethical standards and regulatory compliance in all clinical trials.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Trial Officials
Simeon Kimmel, MD
Principal Investigator
Boston Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported